203 related articles for article (PubMed ID: 30108045)
1. Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.
Yang J; Kumar A; Vilgelm AE; Chen SC; Ayers GD; Novitskiy SV; Joyce S; Richmond A
Cancer Immunol Res; 2018 Oct; 6(10):1186-1198. PubMed ID: 30108045
[TBL] [Abstract][Full Text] [Related]
2. Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.
Neelam S; Mellon J; Wilkerson A; Niederkorn JY
Melanoma Res; 2019 Aug; 29(4):401-412. PubMed ID: 30932943
[TBL] [Abstract][Full Text] [Related]
3. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
[TBL] [Abstract][Full Text] [Related]
5. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
6. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
7. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
8. Mouse CD8
Li Z; Wu Y; Wang C; Zhang M
Cancer Immunol Immunother; 2019 Aug; 68(8):1303-1315. PubMed ID: 31278476
[TBL] [Abstract][Full Text] [Related]
9. Fas ligand on tumor cells mediates inactivation of neutrophils.
Chen YL; Chen SH; Wang JY; Yang BC
J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
[TBL] [Abstract][Full Text] [Related]
10. NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses.
Witalisz-Siepracka A; Gotthardt D; Prchal-Murphy M; Didara Z; Menzl I; Prinz D; Edlinger L; Putz EM; Sexl V
Cancer Immunol Res; 2018 Apr; 6(4):458-466. PubMed ID: 29386186
[TBL] [Abstract][Full Text] [Related]
11. Control of Metastases via Myeloid CD39 and NK Cell Effector Function.
Yan J; Li XY; Roman Aguilera A; Xiao C; Jacoberger-Foissac C; Nowlan B; Robson SC; Beers C; Moesta AK; Geetha N; Teng MWL; Smyth MJ
Cancer Immunol Res; 2020 Mar; 8(3):356-367. PubMed ID: 31992567
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
[TBL] [Abstract][Full Text] [Related]
13. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Front Immunol; 2019; 10():1262. PubMed ID: 31231387
[TBL] [Abstract][Full Text] [Related]
15. TREM2 promotes natural killer cell development in CD3
Lee HY; Lee EH; Yi J; Ji KY; Kim SM; Choi HR; Yee SM; Kang HS; Kim EM
BMC Immunol; 2021 May; 22(1):30. PubMed ID: 33980160
[TBL] [Abstract][Full Text] [Related]
16. Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.
Kitajima M; Abe T; Miyano-Kurosaki N; Taniguchi M; Nakayama T; Takaku H
Mol Ther; 2008 Feb; 16(2):261-8. PubMed ID: 18059370
[TBL] [Abstract][Full Text] [Related]
17. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
[TBL] [Abstract][Full Text] [Related]
18. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche.
Sceneay J; Chow MT; Chen A; Halse HM; Wong CS; Andrews DM; Sloan EK; Parker BS; Bowtell DD; Smyth MJ; Möller A
Cancer Res; 2012 Aug; 72(16):3906-11. PubMed ID: 22751463
[TBL] [Abstract][Full Text] [Related]
19. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation.
Chiu HY; Sun GH; Chen SY; Wang HH; Ho MY; Chu CY; Wu WL; Jhou RS; Tsai YL; Huang RT; Sun KH; Tang SJ
Mol Carcinog; 2013 Sep; 52(9):705-14. PubMed ID: 22488710
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice.
Beider K; Nagler A; Wald O; Franitza S; Dagan-Berger M; Wald H; Giladi H; Brocke S; Hanna J; Mandelboim O; Darash-Yahana M; Galun E; Peled A
Blood; 2003 Sep; 102(6):1951-8. PubMed ID: 12730102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
